Last updated: September 4, 2026
Protriptyline hydrochloride is a mature tricyclic antidepressant with limited commercial activity, no meaningful patent protection, no biosimilar pathway, and little publicly reported product revenue. The branded product, Vivactil, has effectively lost commercial relevance, while any remaining demand is supplied through small-volume generic channels. Market value is driven by legacy prescribing, clinical familiarity, and supply availability rather than innovation, exclusivity, or promotional investment.
What is the current FDA status of protriptyline hydrochloride?
Protriptyline hydrochloride is an oral tricyclic antidepressant approved for depressive illness. It is marketed as tablets, historically in 5 mg and 10 mg strengths. The drug inhibits norepinephrine and serotonin reuptake and has a relatively activating profile compared with more sedating tricyclics.[1]
The branded product, Vivactil, is no longer a significant commercial product in the U.S. market. FDA records identify protriptyline hydrochloride as an older approved prescription medicine, but current commercial availability is limited and may vary by wholesaler, pharmacy, and manufacturer inventory.[2]
| Attribute |
Protriptyline hydrochloride |
| Drug class |
Tricyclic antidepressant |
| Historical brand |
Vivactil |
| Dosage form |
Oral tablet |
| Historical strengths |
5 mg and 10 mg |
| FDA pathway |
Original NDA approval; subsequent generic abbreviated applications |
| Current commercial position |
Mature, low-volume generic market |
| Biosimilar exposure |
None |
| Patent-driven exclusivity |
Expired |
| Primary commercial constraint |
Limited demand and inconsistent supply |
| Main substitutes |
SSRIs, SNRIs, other tricyclic antidepressants |
DailyMed labeling identifies protriptyline hydrochloride as a prescription oral tablet and describes warnings associated with tricyclic antidepressants, including cardiovascular effects, suicidality risk, anticholinergic effects, and overdose toxicity.[1]
When did protriptyline hydrochloride lose exclusivity?
Protriptyline hydrochloride lost meaningful market exclusivity decades ago. Its original compound and product patents, if any, expired long before the modern generic market became the primary supply channel. No current patent estate is known to create a material barrier to generic manufacture or sale.
The commercial position is therefore different from newer branded antidepressants. Generic entry is not waiting for a near-term patent expiry date. It is already legally permitted, subject to FDA approval, manufacturing compliance, and commercial supply economics.
Protriptyline hydrochloride exclusivity timeline
| Period |
Commercial event |
| 1960s |
Original U.S. approval of protriptyline hydrochloride tablets |
| 1970s-1980s |
Brand-led market period |
| 1980s-1990s |
Generic competition and erosion of brand value |
| 2000s |
Declining use as SSRIs and newer antidepressants gained share |
| 2010s |
Increasingly limited commercial availability |
| 2020s |
Legacy generic product with low demand and supply concentration risk |
The original approval predates the Hatch-Waxman framework. Any associated composition-of-matter, formulation, or use patents would have expired under ordinary patent terms. No active Orange Book patent is expected to block an abbreviated new drug application for standard protriptyline tablets.[2][3]
What patents protect protriptyline hydrochloride?
No commercially relevant active U.S. patent estate protects standard protriptyline hydrochloride tablets.
The relevant intellectual-property categories are:
| Patent category |
Current relevance |
| Composition of matter |
Expired |
| Basic tablet formulation |
Expired or commercially immaterial |
| Method of treating depression |
Expired or unenforceable as a market barrier |
| Salt or polymorph protection |
No known active barrier of commercial importance |
| Extended-release formulation |
No established active product category |
| Manufacturing process |
Potentially protectable in theory, but not a barrier to standard generic production |
| Device or delivery system |
Not relevant to the conventional tablet |
Protriptyline is a small-molecule chemical drug, not a biologic. It has no biosimilar exclusivity, reference-product biologic exclusivity, or patent-linked biologic interchangeability issue.
Are formulation patents relevant to protriptyline?
Formulation patents have little commercial significance for the conventional product. The marketed dosage form is a conventional oral tablet, and no differentiated long-acting, transdermal, injectable, or abuse-deterrent formulation has established a significant U.S. market.
A company could seek protection for a modified-release or combination formulation. That strategy would require clinical development, FDA approval, and evidence of sufficient demand. The low prevalence of protriptyline prescribing makes a large formulation investment difficult to justify.
What is the Orange Book status of protriptyline hydrochloride?
The Orange Book is relevant for identifying approved products, therapeutic equivalence ratings, and any listed patents or exclusivity. For an older generic such as protriptyline hydrochloride, the key commercial question is whether an active manufacturer maintains an FDA-approved product with current distribution.[2]
The likely Orange Book profile is characterized by:
- An old reference product associated with Vivactil.
- Generic tablet applications rather than a protected branded product.
- No remaining meaningful new-drug exclusivity.
- No material patent listing that prevents generic competition.
- Potential variation in active product listings as manufacturers enter or leave the market.
Orange Book presence does not guarantee continuous pharmacy availability. A product can remain approved while commercial distribution becomes intermittent or stops. This distinction is important for protriptyline because demand is small and manufacturers may not maintain continuous production.
How many companies manufacture protriptyline hydrochloride?
The number of active commercial manufacturers is difficult to infer from approval records alone. FDA approval, National Drug Code registration, label availability, and current wholesale distribution are separate indicators.
Historically, generic antidepressant suppliers have included large generic manufacturers and contract manufacturers. The relevant commercial participants may change as companies discontinue low-volume products, transfer abbreviated applications, or rely on third-party manufacturing.
The market structure is best described as a thin generic market rather than a broad, actively contested category. Typical characteristics include:
- Few active suppliers.
- Low production runs.
- Limited inventory held by wholesalers.
- High sensitivity to manufacturing interruptions.
- Little promotional spending.
- Minimal incentive to reduce price aggressively.
No major branded pharmaceutical company is known to be investing materially in protriptyline commercialization. The economic opportunity is more likely to involve portfolio maintenance by a generic manufacturer than a standalone launch by an innovative company.
What is the financial trajectory of protriptyline hydrochloride?
Protriptyline has no separately reported revenue stream in the public filings of major pharmaceutical companies. The drug is generally grouped with broader generic portfolios, making product-specific sales difficult to identify from annual reports.
Its financial trajectory is likely:
| Phase |
Financial profile |
| Brand period |
Higher price, physician promotion, and relatively concentrated revenue |
| Early generic period |
Rapid price erosion and volume transfer |
| Mature generic period |
Low unit prices and limited supplier profitability |
| Current period |
Small revenue pool, sporadic demand, and supply-driven pricing |
The principal revenue decline occurred after generic substitution and therapeutic displacement by selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and other newer antidepressants.
Current commercial revenue is likely determined by a narrow patient population, legacy prescribers, psychiatric use in selected cases, and patients who remain stable on the medicine. The product is not a growth asset. Its value is closer to that of a niche maintenance product or portfolio filler.
What drives pricing for protriptyline?
Price formation is affected by:
- Low annual prescription volume.
- Number of active suppliers.
- Pharmacy reimbursement.
- Wholesaler inventory.
- Manufacturing batch economics.
- Shortage risk.
- Prescriber substitution options.
- Patient continuity requirements.
A low-volume generic can produce higher unit prices than a high-volume generic even after patent expiry. Fixed regulatory, quality, packaging, and distribution costs are spread across fewer units. If one or two suppliers exit, the remaining suppliers may face greater pricing power, although demand remains limited.
Which companies are challenging protriptyline hydrochloride?
There is no meaningful current Paragraph IV challenge narrative associated with protriptyline hydrochloride. Paragraph IV litigation is typically relevant when a generic applicant challenges an active Orange Book patent. Protriptyline’s core patents are long expired, so the market does not present the same litigation dynamics seen with newer branded medicines.[3]
Potential generic applicants would generally rely on:
- An ANDA referencing the approved product.
- Paragraph I, II, or III certifications where applicable.
- A Paragraph IV certification only if an active listed patent existed.
- Standard bioequivalence evidence for the tablet product.
No major ongoing patent dispute is central to the commercial outlook of protriptyline hydrochloride.
What patent litigation affects protriptyline hydrochloride?
No material active U.S. patent litigation is known to determine market access for standard protriptyline hydrochloride tablets.
The litigation profile differs from high-value products in several respects:
| Litigation issue |
Protriptyline relevance |
| Paragraph IV challenge |
Low |
| Patent-infringement damages |
Low |
| Formulation dispute |
Low |
| Orange Book delisting dispute |
Low |
| Authorized generic strategy |
Low |
| Antitrust litigation |
Low |
| Manufacturing trade-secret dispute |
Possible in theory, but not a market driver |
The absence of litigation is itself commercially significant. No company has a strong patent position to defend, and no generic entrant faces a credible patent-based launch delay.
What generic entry risks exist for protriptyline hydrochloride?
Generic entry risk is not the main threat because generic entry has already occurred. The principal risks are supply disruption, market exit, and therapeutic substitution.
Supply and manufacturing risks
Protriptyline is vulnerable to:
- Discontinuation by a low-volume manufacturer.
- Active pharmaceutical ingredient sourcing problems.
- Batch failures or quality remediation.
- Product delisting despite continued FDA approval.
- Wholesaler decisions to reduce inventory.
- Inability to achieve adequate manufacturing scale.
For patients and prescribers, these events can create practical switching pressure. For manufacturers, they can create short-term pricing opportunities but not necessarily durable market expansion.
Therapeutic substitution risks
Protriptyline competes with:
- Fluoxetine, sertraline, escitalopram, and other SSRIs.
- Venlafaxine and duloxetine.
- Amitriptyline, nortriptyline, and imipramine.
- Mirtazapine and bupropion.
- Nonpharmacologic treatment and psychiatric combination therapy.
Modern antidepressants generally have stronger prescribing momentum because of broader guideline adoption, more favorable tolerability profiles, and greater familiarity among primary-care physicians. Protriptyline’s activating effects may preserve use in selected patients, but they do not support broad market growth.
How does protriptyline compare with other tricyclic antidepressants?
Protriptyline is less commercially important than amitriptyline and nortriptyline. Those drugs have broader use in pain, migraine prevention, sleep-related prescribing, and psychiatric treatment.
| Drug |
Relative market position |
Common commercial advantage |
| Amitriptyline |
Larger generic market |
Depression, neuropathic pain, migraine, sleep |
| Nortriptyline |
Larger and more established |
Depression and pain; perceived tolerability advantages |
| Imipramine |
Mature niche product |
Depression and enuresis-related use |
| Desipramine |
Small niche |
Selected activating antidepressant use |
| Protriptyline |
Very small niche |
Activating profile and legacy patient continuity |
Protriptyline’s narrow indication profile reduces prescription volume. Unlike amitriptyline, it has limited use outside depression. Unlike newer branded products, it has no differentiated delivery system or protected clinical positioning.
Does protriptyline hydrochloride have biosimilar risk?
No. Biosimilar risk does not apply because protriptyline hydrochloride is a conventional synthetic small molecule. Its competitive risk comes from generic tablets and therapeutic alternatives, not biosimilar products.
FDA approval is governed through the generic-drug framework, generally requiring pharmaceutical equivalence and bioequivalence rather than the biologic comparability process used for biosimilars.[3]
What licensing deals involve protriptyline hydrochloride?
No significant recent licensing transaction involving protriptyline hydrochloride is publicly associated with a major pharmaceutical company. A product transfer, generic application acquisition, or manufacturing agreement could occur without being disclosed as a material transaction.
The low market size reduces the likelihood of:
- A large upfront license.
- A royalty-bearing branded commercialization deal.
- A co-development agreement.
- A regional franchise transaction.
- A platform or combination-product partnership.
Any commercial transaction would more likely involve an asset transfer between generic companies, a contract-manufacturing arrangement, or a portfolio acquisition.
What is the outlook for protriptyline hydrochloride?
The outlook is stable to declining in volume, with potential episodic price increases caused by supply constraints. The drug is unlikely to regain broad market share without a new clinical positioning or delivery innovation.
Base-case scenario
The base case is continued low-volume generic availability, intermittent manufacturer participation, and gradual prescription erosion as clinicians favor newer antidepressants.
Upside scenario
An upside case would require one of the following:
- A clinically differentiated formulation.
- New evidence supporting a specific treatment-resistant population.
- A shortage of alternative tricyclic products.
- A commercial strategy targeting legacy patients and specialist prescribers.
The probability of substantial growth is low because development costs would be difficult to recover from the existing patient base.
Downside scenario
The downside case is commercial discontinuation by remaining suppliers, followed by pharmacy-level shortages and substitution to nortriptyline, amitriptyline, or newer antidepressants.
Key Takeaways
- Protriptyline hydrochloride is a legacy tricyclic antidepressant with limited current commercial demand.
- Vivactil no longer represents a meaningful branded revenue opportunity.
- Core patent and exclusivity rights expired decades ago.
- No active patent estate is expected to block generic entry.
- Paragraph IV litigation is not a major market factor.
- Biosimilar competition does not apply.
- Revenue is not separately disclosed by major pharmaceutical companies.
- The main commercial risk is supply instability, not patent expiry.
- The product is less commercially important than amitriptyline or nortriptyline.
- Growth would require a new formulation, new clinical positioning, or an external supply disruption.
FAQs
Is protriptyline hydrochloride still available in the United States?
Availability is limited and may vary by manufacturer, wholesaler, and pharmacy inventory. FDA approval and commercial availability are separate matters for this mature generic product.[2]
Is Vivactil still marketed?
Vivactil is not a significant current branded product. Any continuing U.S. supply is more likely to come through generic or legacy channels than through active brand promotion.
Can a generic company launch protriptyline without a patent challenge?
Yes. Because the core patent protection has expired, a generic applicant would generally not face a material patent barrier for standard protriptyline hydrochloride tablets.
Is protriptyline hydrochloride used for treatment-resistant depression?
It may be used selectively in patients who require an older tricyclic antidepressant, but current treatment patterns generally favor newer antidepressants and better-established tricyclic alternatives.
Could protriptyline hydrochloride become a shortage product?
Yes. Low demand and a limited supplier base can make a mature generic vulnerable to manufacturing interruptions, even when no patent or regulatory barrier exists.
References
-
DailyMed. (n.d.). Protriptyline hydrochloride tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, 43rd edition. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
